Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) just unveiled an update.
Jacobio Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital as part of a Capital Increase Agreement and Equity Transfer Agreement. This financial boost is expected to enhance the company’s cash reserves and support the development of its innovative oncology therapies, potentially strengthening its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company focused on developing innovative oncology therapies, particularly in targeted oncology and tumor immunotherapy. Their pipeline includes projects in KRAS, Sting, P53, and MYC pathways, with a vision to be a global leader in drug research and development. Jacobio operates R&D centers in Beijing, Shanghai, and Boston, utilizing platforms like the Induced Allosteric Drug Discovery Platform and the immunostimulatory antibody-drug conjugate Platform.
Average Trading Volume: 7,665,464
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.31B
Learn more about 1167 stock on TipRanks’ Stock Analysis page.